Women’s Wellbeing Therapeutics, Evaluation and Marketplace Forecasts to 2016
In 2009, the international women’s wellness (WH) condition therapeutics marketplace was estimated to be well worth .one billion, after acquiring had a Compound Annual Growth Rate (CAGR) of two.6% in between 2001 and 2009. By 2016, the world wide WH condition therapeutics market place is estimated to get to billion, indicating a CAGR of 8.8% between 2009 and 2016. Owing to numerous factors, such as the publication of the Women’s Wellbeing Initiative (WHI) research benefits, a lack of powerful therapeutics, the WH condition therapeutics market place grew moderately in between 2001 and 2009. Even so, the kick off of novel therapeutics in the close to long run is expected to satisfy the unmet require in the market. This will have a pronounced impact on the menopause therapeutics industry.
Amgen Inc’s not long ago released Prolia, a first-in-course drug for the treatment method of postmenopausal osteoporosis, is believed to create revenues of billion yearly. Merck’s Odanacatib, a cathepsin K inhibitor, has also proven promising benefits in postmenopausal osteoporosis therapy. The menopause therapeutics market place is presently dominated by hormone therapeutics that have extremely questionable security profiles. If accredited for therapy and proven to be safer, non-hormones for the therapy of menopause will strongly compete with the at the moment marketed medication and will considerably alter the market dynamics, with the prospective to drive the menopause industry revenue up to .2 billion by 2016. Pfizer, Merck, NPS Pharmaceuticals, Inc., �?terna Zentaris Inc., BioSante and Depomed Inc. have promising line-ups of first-in-class molecules.
The current WH disorder therapeutics pipeline is promising with a powerful line-up of very first-in-course molecules in late phases of clinical advancement this kind of as Pristiq, Aprela, Menerba, Elagolix and Cetrorelix. In addition, the modern launch of possible blockbuster drugs these kinds of as Prolia (Denosumab) for the treatment method of postmenopausal osteoporosis will nullify the impact of significant medications such as Fosamax, Boniva and Actonel dropping their patents. Therefore, the WH problem therapeutics industry is an appealing marketplace with huge opportunities for novel entrants with higher basic safety and efficacy profiles.
GBI Study, a foremost organization intelligence provider, has introduced its most current investigation “Women’s Wellbeing Therapeutics, Evaluation and Market place Forecasts to 2016 – Substantial Unmet Will need will Drive the Uptake of Novel Medicines in the Menopause and Osteoporosis Markets”. The report gives in-depth evaluation of the unmet requires, drivers and barriers that influence the global Women’s Wellbeing (WH) marketplace. The report analyzes the markets for WH disorders in the US, the top rated five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, revenue, prices and volumes are forecast until finally 2016 for the crucial geographies as effectively as the top therapeutic segments. Furthermore, the report supplies aggressive benchmarking for the foremost organizations and analyzes the mergers, acquisitions and licensing agreements that form the world wide markets.
It is created using info and details sourced from proprietary databases, main and secondary research and in-house evaluation by GBI Research’s group of industry authorities.
For further specifics, be sure to click on or add the below website link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=The-Womens-Well being-Therapeutics-Market place-to-2016-High-Unmet-Need-will-Drive-the-Uptake-of-Novel-Medications-in-Menopause-and-Osteoporosis&ReportType=Sector_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
For more specifics contact:
North The united states: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 forty 6616 6782
Source: http://health.articlesinside.co.cc/womens-health-therapeutics-analysis-and-market-forecasts-to-2016
No comments:
Post a Comment